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Disease developmentAmyotrophic lateral sclerosis (ALS) is a late-onset fatal neurodegenerative disease reﬂecting degeneration of
upper and lower motoneurons (MNs). The cause of ALS and the mechanisms of neuronal death are still largely
obscure, thus impairing the establishment of efﬁcacious therapies. Glutamate (Glu)-mediated excitotoxicity
plays a major role in MN degeneration in ALS. We recently demonstrated that the activation of Group I metabo-
tropic Glu autoreceptors, belonging to both type 1 and type 5 receptors (mGluR1 andmGluR5), at glutamatergic
spinal cord nerve terminals, produces excessive Glu release in mice over-expressing human superoxide-
dismutase carrying the G93A point mutation (SOD1G93A), a widely used animal model of humanALS. To establish
whether these receptors are implicated in ALS, we generated mice expressing half dosage of mGluR1 in the
SOD1G93A background (SOD1G93AGrm1crv4/+), by crossing the SOD1G93A mutant mouse with the Grm1crv4/+
mouse, lacking mGluR1 because of a spontaneous recessive mutation. SOD1G93AGrm1crv4/+ mice showed
prolonged survival probability, delayed pathology onset, slower disease progression and improvedmotor perfor-
mances compared to SOD1G93Amice. These effects were associated to reduction ofmGluR5 expression, enhanced
number of MNs, decreased astrocyte and microglia activation, normalization of metallothionein and catalase
mRNA expression, reduced mitochondrial damage, and decrease of abnormal Glu release in spinal cord of
SOD1G93AGrm1crv4/+compared to SOD1G93A mice. These results demonstrate that a lower constitutive level of
mGluR1 has a signiﬁcant positive impact on mice with experimental ALS, thus providing the rationale for future
pharmacological approaches to ALS by selectively blocking Group I metabotropic Glu receptors.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. MPA, α-amino-3-hydroxy-5-
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Amyotrophic lateral sclerosis (ALS) is a progressive neuromuscular
disorder characterized by degeneration of cortical, brainstem and spinal
motoneurons (MNs) leading to muscle wasting, weakness and spastici-
ty. ALS has an incidence of approximately 1–2 new cases per 100,000 in-
dividuals every year and is most commonly sporadic, although familial
forms have been reported in about 10% of cases (Andersen and Al-
Chalabi, 2011). The ﬁrst identiﬁed ALS-linked gene is the superoxide
dismutase-1 (SOD1) that accounts for about 20% of patients with famil-
ial ALS (Birve et al., 2010; Rosen et al., 1993). So far, at least other ﬁfteen
genes involved in different cellular pathways have been associated
to ALS, thus indicating that, even though pathogenic mechanisms
are still elusive, multiple cellular events contribute to the disease
(Andersen and Al-Chalabi, 2011). These events include oxidative stress,se. 
49M. Milanese et al. / Neurobiology of Disease 64 (2014) 48–59mitochondrial dysfunction, protein aggregation, impaired anterograde
and retrograde transport, neuroinﬂammation, dysregulated RNA signal-
ing, and glutamate(Glu)-mediated excitotoxicity (Cleveland et al.,
1996; Ferraiuolo et al., 2011).
Glu exerts its actions through activation of ionotropic and metabo-
tropic receptors. Three ionotropic receptor families, namely the
Ca2+-permeant N-methyl-D-aspartate (NMDA) receptor, and the
preferentially Na+-permeant α-amino-3-hydroxy-5-methyl-4-
isoxazole propionate (AMPA) and kainate receptors, exist as multiple
heteromers formed by the co-assembly of different subunits (Conti
and Weinberg, 1999; Dingledine et al., 1999). Metabotropic glutamate
receptors (mGluR) are also heterogeneous and classiﬁed into three
groups, based on their sequence homology, signaling and pharmacolo-
gy (Connand Pin, 1997; Nicoletti et al., 2011). Group ImGluRs, compris-
ing mGluR1 and mGluR5, are excitatory because of positive coupling to
phosphatidylinositol breakdown (Conn and Pin, 1997; De Blasi et al.,
2001; Ferraguti et al., 2008). Thus, hyper-activation of Glu receptors
may lead to an excessive increase of intracellular calcium due to either
its entry through ionotropic Glu receptors and/or to its release from in-
tracellular stores, mediated by Group I mGluRs and contributing to
excitotoxicity and cell death (Doble, 1999).
Evidence implicating Glu-mediated excitotoxicity in ALS is mainly
based on the presence of elevated levels of extracellular Glu in a high
percentage of sporadic and familial ALS patients (Perry et al., 1990),
on the reduced expression of the Glu transporter type 1 (GLT1) in the
affected areas of the CNS (Rothstein et al., 1992, 1995) and on the obser-
vation that ameliorating excitotoxicity is to date the only clinically-
adopted strategy to slow down disease progression in ALS (Cheah
et al., 2010).
The molecular mechanisms of MN degeneration in ALS have been
largely investigated in the subtype of disease caused by SOD1 muta-
tions. Mouse models expressing mutated SOD1 reproduce most of the
pathogenic processes underlying human ALS, including unfolded pro-
tein response activation (Wang et al., 2011a), altered AMPA receptor
subunit expression (Tortarolo et al., 2006), reduced expression and ac-
tivity of GLT1 (Boston-Howes et al., 2006), loss of astrocytic regulation
GluR2 expression in MNs (Van Damme et al., 2007), impaired calcium
buffering inmitochondria (Damiano et al., 2006) defective axonal trans-
port (Bilsland et al., 2010), and Glu mediated excitotoxicity (Heath and
Shaw, 2002). In addition, our recent studies with mice expressing
human SOD1 carrying the G93A point mutation (SOD1G93A), the most
widely used animal model for human ALS, indicate that Glu release is
abnormally high in the spinal cord of these animals upon exposure to
different releasing stimuli, including nerve terminal depolarization
(Milanese et al., 2011; Raiteri et al., 2004). We have recently shown
that activation of presynaptic autoreceptors, belonging to mGluR1 and
mGluR5 types, by submicromolar concentrations of the mGluR1/5 ago-
nist 3,5-DHPG, promoted an excessive Glu release in the spinal cord of
SOD1G93A mice compared to controls (Giribaldi et al., 2013).
Here, we sought to explore whether excessive Group I mGluR ac-
tivity plays a role in the pathogenesis of ALS. To this end we crossed
SOD1G93A mice with mice lacking the mGluR1 (Grm1crv4/+; Conti et al.,
2006) obtaining double mutants expressing the SOD1G93A mutated
gene and half dosage of mGluR1 (SOD1G93AGrm1crv4/+).
Materials and methods
Animals
Grm1crv4 mice line carrying a recessive loss-of-function mutation
(crv4) in the gene (Grm1) coding for mGluR1 were used to prepare
SOD1G93AGrm1crv4/+ double mutants. The crv4mutation is a spontane-
ous recessivemutation occurring in the BALB/c/Pas inbred strain. It con-
sists of an insertion of a retrotransposon LTR (Long Terminal Repeat)
fragment occurring in intron 4 of theGrm1 gene and causing the disrup-
tion of the gene splicing and the absence of the receptor protein (Contiet al., 2006). Affected (Grm1crv4/crv4) and control (Grm1+/+) mice
were maintained on the same genetic background by intercrossing
Grm1crv4/+ mice. The genotype of Grm1crv4mice was identiﬁed by PCR
using speciﬁc primers as already reported (Conti et al., 2006).
B6SJL-Tg(SOD1*G93A)1Gur mice expressing high copy number of
mutant human SOD1 with a Gly93Ala substitution (SOD1G93A mice)
(Gurney et al., 1994) were originally obtained from Jackson Labora-
tories (Bar Harbor, ME, USA). Transgenic male mice were crossed
with background-matched B6SJL wild-type females and selective
breeding maintains the transgene in the hemizygous state. Trans-
genic mice are identiﬁed analyzing tissue extracts from tail tips as
previously described (Stifanese et al., 2010). SOD1G93A male mice
(on a mixed C57BL6-SJL background) were bred with Grm1crv4/+
females (BALB/c background) to generate double-mutants carrying
the Grm1crv4/+ heterozygous mutation and the SOD1*G93A trans-
gene (SOD1G93AGrm1crv4/+). All experiments were conducted on lit-
termates derived from this last breeding (Fig. 1A). Animals were
housed at constant temperature (22 ± 1 °C) and relative humidity
(50%) with a regular 12 h–12 h light–dark cycle (light 7 AM–
7 PM), throughout the experiments. Food (type 4RF21 standard
diet obtained from Mucedola, Settimo Milanese, Milan, Italy) and
water were freely available. All experiments were carried out in ac-
cordance with the European Communities Council Directive of 24
November 1986 (86/609/EEC). All efforts were made to minimize
animal suffering and to use only the number of animals necessary
to produce reliable results. Sexes were balanced in each experimen-
tal group to avoid bias due to sex-related intrinsic differences in
disease severity. For experimental use animals were killed at symp-
tomatic stage of disease (19 weeks). A total number of 30 WT, 55
SOD1G93A, 55 SOD1G93AGrm1crv4/+, and 30 Grm1crv4/+ mice were
used in this study.
Survival and motor performance
Survival time was identiﬁed as the time at which mice were un-
able to right itself within 20 seconds when placed on their side.
The effects of the genetic manipulation on the progression of the dis-
ease symptoms were analyzed by Rotarod task and motor deﬁcits.
Each clinical test registration was started on day 90 and data were
recorded three times a week, until death, in WT, SOD1G93A,
SOD1G93AGrm1crv4/+, and Grm1crv4/+ mice. Tests were performed in
randomized order by blinded observers. Rotarod test: starting on
day 90, the time for which an animal could remain on the rotating
cylinder was measured using an accelerating Rotarod apparatus
(Rota-Rod 7650; Ugo Basile, Comerio, Italy). In this procedure the
rod rotation gradually increases in speed from 4 to 40 rpm over
the course of 5 min. The time that the mice stayed on the rod until
falling off was recorded. Before registration animals were trained
for 10 days. Motor deﬁcits: mice were rated for disease progression
by scoring the extension reﬂex of hind limbs and the gait. In the
extension reﬂex test, animals were evaluated by observing the
hind limb posture when suspended by the tail. Gait deﬁcits were
measured by observing mice in an open ﬁeld. Motor deﬁcits were
rated using a 5 point score scale (5, no sign of motor dysfunction;
0, complete impairment) as previously described (Uccelli et al.,
2012). Body weight: Body weight was measured immediately before
behavioral tests. Disease onset was deﬁned retrospectively as the
time when mice reached peak of body weight (Boillée et al.,




Nineteen-weekold WT, SOD1G93A, SOD1G93AGrm1crv4/+, andGrm1crv4/+
mice were anesthetized with choral hydrate (300 mg/kg) and perfused
Fig. 1. Grm1crv4/+and SOD1G93Amouse cross and expression of mGluR1 and mGluR5 in spinal cord of WT, SOD1G93A, SOD1G93AGrm1crv4/+ and Grm1crv4/+ mice. Four genetically different
mouse littermates (WT, SOD1G93A, SOD1G93AGrm1crv4/+Grm1crv4/+) were obtained by crossing Grm1crv4/+ and SOD1G93A mice and used for experimental studies (A). Expression of
mGluR1 (B and D) andmGluR5 (C and E) in spinal cord lysates was quantiﬁed by SDS-PAGE andWestern blotting. Mouse anti-mGluR1monoclonal antibody or rabbit anti-mGluR5 poly-
clonal antibody was used. mGluR1 andmGluR5 bands were normalized for Gapdh. Representative immunoreactive bands and quantitative analysis (bar plots) are reported. The expres-
sion of mGluR1 was halved and that of mGluR5 was reduced by about 30% in both Grm1crv4/+ and SOD1G93AGrm1crv4/+ mice compared to age-matched WT and SOD1G93A animals,
respectively. Data are means ± SEM of 7 independent experiments (7 mice per group). *p b 0.05, **p b 0.01 vs. SOD1G93A; #p b 0.05 vs. WT (Mann–Whitney).
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phosphate buffer (PB, pH 7.4). Spinal cords were post-ﬁxed for 24 h
in the same solution at 4 °C and then transferred to a solution contain-
ing 30% glycerol, 30% ethylene glycol, 30% distilled water and 10% PB
and subsequently stored at −20 °C. Spinal cords were cut coronally
into 50-μm-thick sections with a Vibratome; sections were collectedinto groups of ten. One section/group was stained with 0.1% thionine;
subsequently, cervical, thoracic, lumbar and sacral spinal cord levels
were identiﬁed by lightmicroscopic examination using a Leitz Orthoplan
(Wetzlar, Gemany) microscope (Watson et al., 2008). Selected serial
lumbar spinal cord levels (L4/L5) were post-ﬁxed in 1% osmium tetrox-
ide in PB for 45 min, and contrasted with 1% uranyl acetate in maleate
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sections were embedded in Epon/Spurr resin (Electron Microscopy Sci-
ences, Hatﬁeld, PA, USA), ﬂattened between Aclar sheets (Electron Mi-
croscopy Sciences) and polymerized at 60 °C for (48 h). Small blocks
of tissue containing ventral horn and ventrolateral funiculus (Jaarsma
et al., 2000) were selected by light-microscopic inspection, glued to
blank epoxy and sectioned with an ultra-microtome (MTX; Research
and Manufacturing Company Inc., Tucson, AZ, USA). Ultrathin sections
(60 nm) were collected and mounted on 200 mesh copper grids,
stained with uranyl acetate and Sato's lead and examinedwith a Philips
EM 208 electron microscope coupled to a MegaViewII high-resolution
CCD camera (Soft Imaging System; Munster, Germany).
Data analysis
For light microscopy studies, number of 0.1% thionine positive
alpha-motoneurons in ventrolateral horn of L4/L5 was estimated
using serial 50 μm sections fromWT (17 sections/2 animals), SOD1G93A
mutant (14 sections/3 animals), SOD1G93AGrm1crv4/+double mutant
(14 sections/3 animals) and Grm1crv4/+ mice (15 sections/2 animals).
Microscopic ﬁelds of ventrolateral horns were captured with a digital
camera coupled to Leitz Orthoplan microscope; alpha-motoneurons
were selected and counted based on diameters greater than 25 μm
using ImageJ version 1.29 software (NIH, Bethesda, MD, USA). For elec-
tronmicroscopy analysis, themorphology of both normal and abnormal
mitochondria in neuronal perikarya, dendrites, myelinated axons and
axon terminals of selected motoneurons was studied. For each experi-
mental group (10–12 ultrathin sections/animal; 3 animals) quantitative
data on normal and swollen/vacuolated mitochondria were gathered
from the analysis of at least 40 microscopic ﬁelds/compartment, corre-
sponding to a total area of about 800 μm2for each experimental condi-
tion. Microscopic ﬁelds were randomly selected and captured at
18,000 or 22,000×. To determine the relative density of normal and
swollen/vacuolated mitochondria, areas of each cellular compartment
were calculated using ImageJ version 1.29 software (NIH, Bethesda,
MD, USA); normal and abnormal mitochondria were identiﬁed and
counted as previously described (Jaarsma et al., 2000; Sasaki et al.,
2004).
Quantiﬁcation of protein expression
Spinal cord from 19-week old WT, SOD1G93A, SOD1G93AGrm1crv4/+,
and Grm1crv4/+mice were dissected and homogenized in lysis buffer
(10 mM Tris, pH 8.8, 20% glycerol, 2% sodium dodecyl sulfate, 0.1 mM
EDTA, 5% β-mercaptoethanol). Protein concentration was determined
according to Bradford (1976). Appropriate amount of total protein
was separated by means of SDS-polyacrylamide gel electrophoresis.
The concentration of proteins in each sample felt in the linear portion
of the curve. A triplicate analysis for each sample was performed.
Electroblotted proteins were monitored using Naphthol blue black
staining (Sigma-Aldrich, St Louis, MO, USA). Membranes were then
incubated with the following antibodies: anti-Glial Fibrillar Acidic
Protein (GFAP) mouse monoclonal antibody (1:5000; Sigma Aldrich,
St Louis, MO, USA); anti-ionizing calcium-binding adaptor molecule 1
(IBA-1) goat polyclonal antibody (1:1000; Abcam, Cambridge, UK);
anti-mGluR1 mouse monoclonal antibody (1:2500; BD Biosciences, San
Jose, CA, USA); anti-mGluR5 rabbit polyclonal antibody (1:10000,
Epitomics, Burlingame, CA, USA); anti-GLT1mousemonoclonal antibody
(1:5000), and anti-Gapdh mouse monoclonal antibody (1:10000;
Millipore, Billerica, MA, USA). After incubation with appropri-
ate peroxidase-coupled secondary antibodies, protein bands were de-
tected by using a Western blotting detection system (ECL Advance™;
Amersham Biosciences, Piscataway, NJ, USA). Bands were detected
and analyzed for density using an enhanced chemiluminescence system
(Versa-Doc 4000; Bio-Rad, Segrate, Milan, Italy), and Quantity One
software (Bio-Rad). Bands of interest were normalized for Gapdh level
in the same membrane.Quantiﬁcation of gene expression
Spinal cord from 19-week old WT, SOD1G93A, Grm1crv4/+,
SOD1G93AGrm1crv4/+mice were dissected, quickly frozen in liquid
nitrogen and stored at −80 °C until use. Total RNA was isolated by
means of the acid phenol-chloroform procedure, using the Trizol re-
agent (Sigma Aldrich, St Louis, MO, USA) according to the manufac-
turers' instructions, converted to cDNA and ampliﬁed with the
Chromo 4TM System real-time PCR apparatus (Biorad, Milan, Italy,
17). Analysis of the expression levels of metallothionein 1, 2, 3
(MT-1, MT-2, MT-3) and catalase genes was carried out as previously
described (Lanza et al., 2009). Real-time PCR reactions were per-
formed in a ﬁnal volume of 20 μL containing 10 ng cDNA, 10 μL of
iTaq SYBR Green Supermix with ROX (Bio-Rad), and 0.25 μM of
each primer pair (TIB MolBiol, Genoa, Italy). Glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) was used as reference gene.
The mRNA expression levels of MTs and catalase of each experimen-
tal group of mice were normalized to Gapdh and represented as rel-
ative to the WT mice (normalized fold change).
Release experiments
WT, SOD1G93A, SOD1G93AGrm1crv4/+, and Grm1crv4/+ 19-week old
mice were sacriﬁced, the spinal cord rapidly dissected and synapto-
somes prepared and puriﬁed as previously described (Giribaldi et al.,
2013). Synaptosomes were resuspended in physiological medium
and labeled with 0.05 μM [3H]D-Asp, used as a tracer of the intra-
terminal pools of Glu (Fleck et al., 2001). Aliquots were distributed on
microporous ﬁlters placed at the bottom of a set of parallel superfusion
chambers maintained at 37 °C (Superfusion System, Ugo Basile,
Comerio, Varese, Italy; Raiteri et al., 1984) and the effect of (S)-3,5-
Dihydroxyphenylglycine (3,5-DHPG; 0.3 and 30 μM) on [3H]D-Asp re-
lease was studied. Superfusion was started with physiological medium
at a rate of 0.5 ml/min and continued for 48 min. After 36 min of
superfusion to equilibrate the system, ﬁve 3-min samples were collect-
ed. (S)-3,5-Dihydroxyphenylglycine (3,5-DHPG; 0.3 and 30 μM)was in-
troduced at the end of the ﬁrst sample collected (t = 39 min) and
maintained until the end of the experiment. Collected samples and
superfused synaptosomes were counted for radioactivity. Tritium re-
leased in each samplewas calculated as fractional rate × 100 (percentage
of the total synaptosomal neurotransmitter content at the beginning of
the respective collection period). Drug effectswere evaluated by calculat-
ing the ratio between the efﬂux in the fourth sample collected (in which
the maximum effect of 3,5-DHPG was generally reached) and the efﬂux
of the ﬁrst fraction (basal efﬂux). This ratio was compared to the corre-
sponding ratio obtained under resting conditions. Appropriate controls
were always run in parallel.
Statistics
Data are expressed as mean ± SEM and p value b0.05 was consid-
ered signiﬁcant. The Kaplan–Meier plot was used to evaluate survival
probability and cumulative curves were compared using the log-rank
test. The Mann Whitney test was used to compare two mean popula-
tions. Multiple comparisons were performed using the analysis of vari-
ance (ANOVA) followed by Bonferroni or Barlett post hoc test. Analyses
were performed bymeans of Graph Prism (GraphPad Software, Inc., San
Diego, CA, USA) and SigmaStat (Systat Software, Inc., San Jose, CA, USA)
softwares.
Results
Generation of SOD1G93A Grm1crv4/+ mice
To obtain mice expressing the human G93A-mutated SOD1 and half
dosage of mGluR1, we crossed SOD1G93A transgenic mice with the
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(crv4) in the gene (Grm1) coding for mGluR1, thus obtaining four differ-
ent genotypes (Fig. 1A). Grm1crv4/crv4 homozygousmice present substan-
tial motor coordination deﬁcits, while heterozygous Grm1crv4/+ do not
exhibit anomalous neurological phenotype. Heterozygous Grm1crv4/+
mice carrying the SOD1G93A transgene (SOD1G93AGrm1crv4/+ double
mutants) from the initial crossing were then crossed with Grm1crv4/+
animals. All genotypes were born at the expected Mendelian ratio and
were indistinguishable from wild-type littermates at birth, with the ex-
ception of Grm1crv4/crv4 mice that showed impaired coordination of
hind limbs, reduced size and shorter life span, particularly evident in
the double mutants SOD1G934Grm1crv4/crv4. To answer the question
whether the reduced expression of mGluR1 improved the phenotype
of SOD1G93A mice, we focused on mice carrying only one functional
allele of mGluR1, SOD1G93AGrm1crv4/+, and we no longer considered
the SOD1G93AGrm1crv4/crv4 mice, thus avoiding to add the deleterious
neurological effects due to the complete absence of mGluR1 to the
SOD1G93A neurological phenotype.Fig. 2. Survival anddisease progression in SOD1G93A and SOD1G93AGrm1crv4/+mice. Survival time
placed on their side. Twenty-eight mice per group were used. Kaplan–Meyer analysis was used
signiﬁcant at p b 0.001 (Log-rank test). Bodyweight (B)wasmeasured immediately before beh
of body weight in pathological animals as hallmark of disease onset. Rotarod (C), hind limbs e
gression. Animals were tested 3 days a week starting on day 90. Falling off time was recorded
extension and gait impairment observations (Uccelli et al., 2012). Survival probability and
SOD1G93Amice, indicating a slower disease progression. The decrease of body weight took place
onset. Data reported in B–E are means ± SEM of 12 mice per group; *p b 0.05 at least vs. WT;Spinal cord lysates of SOD1G93A and SOD1G93AGrm1crv4/+ mice were
analyzed for mGluR1 (Fig. 1B) or mGluR5 (Fig. 1C) expression. The re-
sults obtained highlighted that mGluR1 expression was halved in
SOD1G93AGrm1crv4/+ compared to SOD1G93A mice. Interestingly, also
mGluR5 expression was reduced by almost 30%,when comparing the
samemouse groups. As expected, mGluR1 was halved in Grm1crv4/+ re-
spect to WT mice (Fig. 1D). A similar reduction was observed when
studying the expression of mGluR5 in Grm1crv4/+ vs. WT mice (Fig. 1E).
Survival and motor functions are improved in SOD1G93AGrm1crv4/+mice
Decreasing mGluR1 expression signiﬁcantly prolonged the life span
of SOD1G93AGrm1crv4/+ doublemutants compared to SOD1G93Amice. The
Kaplan–Meier survival probability curve is reported in Fig. 2A.
Starting around day 115 of life, SOD1G93A mice showed a signiﬁ-
cant decrease of body weight compared to WT mice (Fig. 2B). The de-
crease of body weight became signiﬁcant only around day 140 in
SOD1G93AGrm1crv4/+mice.Weight decrease was always less pronouncedwas assumed as the timewhenanimalswere unable to right itself within 20 secondswhen
to determine survival probability (A). The difference between Kaplan–Meyer curves was
avioral tests. The bodyweight ofWTmicewas alsomeasured to determine the relatedpeak
xtension reﬂex (D) and gait impairment (E) were analyzed to determine the disease pro-
in Rotarod experiments. Animals were rated according to a 5–0 score scale in hind limb
behavioral abilities were signiﬁcantly augmented in SOD1G93AGrm1crv4/+ compared to
later in SOD1G93AGrm1crv4/+ compared to SOD1G93Amice, indicating a delay in the disease
#p b 0.05 at least vs. SOD1G93A (Mann–Whitney Rank Sum Test).
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of weight loss between SOD1G93AGrm1crv4/+ and SOD1G93A suggests that
halving the dosage ofmGluR1 in SOD1G93Amice delays the disease onset
(Boillée et al., 2006b).
To verify whether the reduction of mGluR1 expression slowed dis-
ease progression, we subjected SOD1G93A and SOD1G93AGrm1crv4/+
mice to a number of behavioral tests, such as Rotarod, posterior limb
extension reﬂex, gait impairment. As expected, the performance of
SOD1G93A mice in Rotarod (Fig. 2C), extension reﬂex (Fig. 2D) and gait
impairment (Fig. 2E) tasks were superimposable to that of control
healthymice (not shown in the ﬁgure) until around day 80, then it rap-
idly worsened. Interestingly, SOD1G93AGrm1crv4/+ mice performed sig-
niﬁcantly better than SOD1G93A mice in all tasks (Figs. 2C–E). All
together, behavioral tests suggest that halving the dosage of mGluR1
in SOD1G93Amice results in a remarkable slowing down of the neurolog-
ical ALS phenotype progression.
Motoneurons are preserved in SOD1G93AGrm1crv4/+ mice
Since one of the main features of ALS is the progressive loss of
spinal MNs (Shaw and Eggett, 2000), we assessed their number by
light microscopic inspection of ventral horns in lumbar spinal cord
sections (L4/L5) of WT, SOD1G93A, SOD1G93AGrm1crv4/+ and Grm1crv4/+
mice. This analysis revealed comparable gross histological features in
WT andGrm1crv4/+mice, low tissue preservation associatedwith severe
neuronal loss in SOD1G93A mice, and intermixable histological features
in SOD1G93AGrm1crv4/+mice (Fig. 3, left). The number ofMNswas signif-
icantly increased in SOD1G93AGrm1crv4/+ doublemutantmice, compared
to SOD1G93Amice (Fig. 3, right). MN number was 28.6 ± 1.0, 4.8 ± 0.4,
11.8 ± 0.5 and 27.7 ± 1.5 in WT, SOD1G93A, SOD1G93AGrm1crv4/+, and
Grm1crv4/+mice, respectively. These ﬁndings indicate that halving the
dosage of mGluR1 in SOD1G93A mice preserves MNs from death.
Astrogliosis and microgliosis are reduced in SOD1G93AGrm1crv4/+ mice
Astrocyte activation and microgliosis are key features of ALS
(Lasiene and Yamanaka, 2011; Rossi et al., 2008). We investigated the
expression of GFAP and IBA-1, as markers for reactive astrocytes and
microglia, respectively, in WT, SOD1G93A, SOD1G93A Grm1crv4/+and
Grm1crv4/+ mice. The expression of GFAP was signiﬁcantly higher
in SOD1G93A mice compared to WT and Grm1crv4/+ control mice and
GFAP over-expression was reversed in SOD1G93AGrm1crv4/+mice
(Fig. 4A). Similarly, the expression of IBA-1 was higher in SOD1G93AFig. 3.Number of motoneurons in spinal cord fromWT, SOD1G93A, SOD1G93AGrm1crv4/+ and Grm
Spinal cordswere post-ﬁxed and stored at−20 °C. Lumbar (L4/L5) sections (50 μm-thick)were
greater than 25 μm. Representative photomicrographs of lumbar spinal cord sections (left; scale
rons observed in SOD1G93Amicewas signiﬁcantly reduced in SOD1G93AGrm1crv4/+mice. Data are
SOD1G93A (one-way ANOVA and Bartlett's post-hoc tests).mice compared to WT and Grm1crv4/+ mice and it was reduced back
to control levels in SOD1G93AGrm1crv4/+mice (Fig. 4B). The above results
suggest that halving the dosage of mGluR1 in SODG93A background pro-
duces normalization of astrocyte and microglia activation.The reduction of GLT1 expression is not rescued in SOD1G93AGrm1crv4/+
mice
GLT1 expression is reduced in animal models of ALS and in patients
(Dunlop et al., 2003; Howland et al., 2002; Rothstein et al., 1995). We
measured the expression of the glutamate transporters in the spinal
cord of WT, SOD1G93A, SOD1G93A Grm1crv4/+and Grm1crv4/+ mice. As ex-
pected, the expression of GLT1 was signiﬁcantly lower (about 40%) in
SOD1G93A mice vs. WT mice and also when compared to Grm1crv4/+
mice. GLT1 expression was not modiﬁed in SOD1G93AGrm1crv4/+ respect
to SOD1G93Amice (Fig. 5). These results suggest that halving the dosage
of mGluR1 in SODG93A background does not interfere with GLT1
expression.Metallothionein mRNA expression and catalase are normalized in
SOD1G93AGrm1crv4/+ mice
It is known that the G93Amutation in SOD1 leads to oxidative stress
(Robberecht, 2000). We monitored the mRNA expression of MT1, MT2
and MT3, as markers for oxidative stress in the spinal cord of WT,
SOD1G93A, SOD1G93AGrm1crv4/+ and Grm1crv4/+ mice (Gong and Elliott,
2000; Uccelli et al., 2012). ThemRNA coding for all MTswas signiﬁcant-
ly increased in the spinal cord of SOD1G93A compared to both WT and
Grm1crv4/+ control mice (Figs. 6A,B,C). MT mRNA expression did
not change signiﬁcantly between Grm1crv4/+ and WT mice. Of note,
SOD1G93AGrm1crv4/+ mice displayed a down-regulation of the MT
mRNA expression and this reduction was signiﬁcant for MT1 and MT3
(Figs. 6A and C).
It has been reported that an impairment of catalase (CAT) activity in
both sporadic ALS and familial ALS patients is an index of impaired anti-
oxidant mechanisms (Babu et al., 2008; Nikolić-Kokić et al., 2006). In-
terestingly, we found a signiﬁcant decrease of CAT mRNA expression
in SOD1G93A respect to WT mice and this reduction was reverted in
SOD1G93AGrm1crv4/+ (Fig. 6D). No differences were measured between
Grm1crv4/+ and WT mice. These data suggest that halving the dosage
of mGluR1 in SODG93A background produced normalization of MTs and
CAT mRNA expression.1crv4/+mice. Mice were anesthetized and perfused transcardially with paraformaldehyde.
stainedwith thionine. Alpha-motoneuronswere selected and countedbased ondiameters
bar 100 μm) and quantitative analysis (right) are reported. The dramatic loss ofmotoneu-
means ± SEMof 15 sections, at least, from3mice per group.*p b 0.01 vs.WT; #p b 0.01 vs.
Fig. 4. Astrogliosis and microgliosis in spinal cord fromWT, SOD1G93A, SOD1G93AGrm1crv4/+ and Grm1crv4/+mice. The expression of GFAP (A) and IBA-1 (B) was measured as an index of
astrogliosis and activated microglia, respectively. GFAP and IBA-1 were determined in lumbar spinal cord homogenates by SDS-PAGE and Western blotting using a mouse anti-GFAP
monoclonal antibody or a goat anti-IBA-1 polyclonal antibody. Representative immunoreactive bands (left panels) and quantitative analysis (right panels) are reported. Over-
expression of both GFAP and IBA-1 detected in SOD1G93A mice was almost normalized in SOD1G93AGrm1crv4/+ mice. Data are means ± SEM of 6 independent experiments (6 mice per
group).*p b 0.005 vs. WT; #p b 0.01, ##p b 0.005 vs. SOD1G93A (one-way ANOVA and Bonferroni's post-hoc tests).
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Electron microscopy analysis of perikarya, dendrites, myelinated
axons and axon terminals of motoneurons was performed to quanti-
fy the degree of mitochondrial abnormalities, a sensitive index ofFig. 5.Glutamate transporter 1 expression in spinal cord fromWT, SOD1G93A, SOD1G93AGrm1crv4/+
enates by SDS-PAGE andWestern blotting using amouse anti-GLT1monoclonal antibody. Repr
reported. The expression of GLT1was reduced in SOD1G93A and SOD1G93AGrm1crv4/+mice with r
mice per group).*p b 0.05 vs. WT; #p b 0.05 vs. SOD1G93A (one-way ANOVA and Bonferroni's pneurodegenerative progression (Cozzolino and Carrì, 2012). Fig. 7A
illustrates representative electronmicrographs obtained in L4/L5 spinal
cord sections from WT, SOD1G93A, SOD1G93AGrm1crv4/+ and Grm1crv4/+
mice. As shown in Fig. 7B, the density of normal mitochondria was
signiﬁcantly lower and that of swollen/vacuolated mitochondriaandGrm1crv4/+mice. The expression of GLT1wasmeasured in lumbar spinal cordhomog-
esentative immunoreactive bands (left panels) and quantitative analysis (right panels) are
espect toWT or Grm1crv4/+mice. Data aremeans ± SEM of 4 independent experiments (4
ost-hoc tests).
Fig. 6.Metallothionein and catalasemRNA expression in spinal cord fromWT, SOD1G93A, SOD1G93AGrm1crv4/+ and Grm1crv4/+mice. The expression of metallothioneins (MT1 panel A, MT2
panel B andMT3 panel C) and catalase (CAT, panel D) were detected in lumbar spinal cord extracts by RT-PCR. Gapdhwas used as reference gene. Gene expression is reported as relative
mRNA amount (normalized fold change) compared to WT mice. Over-expression of MTs mRNA and CAT mRNA down regulation detected in SOD1G93A mice are normalized in
SOD1G93AGrm1crv4/+mice. Data are means ± SEM of 5 independent experiments (5 mice per group; 2 mRNA extractions for each mouse). *p b 0.05, **p b 0.01, ***p b 0.001 vs. WT;
#p b 0.05, ##p b 0.005,###p b 0.001 vs. SOD1G93A (one-way ANOVA and Bonferroni post-hoc tests).
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cordingly, the number of swollen/vacuolated mitochondria was signiﬁ-
cantly lower in SOD1G93AGrm1crv4/+ and Grm1crv4/+ compared with
SOD1G93A mice and it was not signiﬁcantly different comparing
SOD1G93AGrm1crv4/+ to WT or Grm1crv4/+mice. In dendrites, the density
of normal mitochondria differed between WT and SOD1G93A and be-
tween SOD1G93A and Grm1crv4/+mice, but not between SOD1G93A and
SOD1G93AGrm1crv4/+. The number of swollen/vacuolated mitochondria
was signiﬁcantly higher in SOD1G93A when compared to the other
experimental groups, which did not differ signiﬁcantly. In axons, the
density of normal mitochondria differed in WT compared to SOD1G93A
and in SOD1G93A compared to Grm1crv4/+ mice, but not between
SOD1G93A and SOD1G93AGrm1crv4/+mice, in spite of the robust difference
observed. A signiﬁcant difference was also found between WT
and SOD1G93AGrm1crv4/+mouse normal mitochondria. The density of
swollen/vacuolated mitochondria in axons was signiﬁcantly different
only betweenWTand SOD1G93A groups. As far as the number of the nor-
mal mitochondria in axon terminals is concerned, signiﬁcant differ-
ences were observed between SOD1G93A and WT, SOD1G93AGrm1crv4/+
and SOD1G93A, and between Grm1crv4/+ and SOD1G93AGrm1crv4/+,
Grm1crv4/+ and WT groups. The density of swollen/vacuolated mito-
chondria in axon terminals was signiﬁcantly different only when WT
and SOD1G93A mice were compared.
Summarizing the data described in Fig. 7, both perikarya and den-
drites displayed a reduction of swollen/vacuolated mitochondria and
an increase of normal mitochondria in SOD1G93AGrm1crv4/+ compared
to SOD1G93A mice. Axons of SOD1G93AGrm1crv4/+ mice showed a small
non-signiﬁcant increase of normal mitochondria and a small non-
signiﬁcant decrease of swollen/vacuolated mitochondria compared to
SOD1G93A mice. Axon terminals of SOD1G93AGrm1crv4/+ mice showed an
increase of normal mitochondria density compared to SOD1G93A and adecrease, though not signiﬁcant, of swollen/vacuolated mitochondria.
Thus, halving the dosage of mGluR1 in SOD1G93A background results in
the histological amelioration of mitochondria characteristics.
Excessive [3H]D-aspartate release
is normalized in SOD1G93AGrm1crv4/+ mice
Our previous study demonstrated an excessive Glu release evoked
by mGluR1 and mGluR5 activation in synaptosomes puriﬁed from lum-
bar spinal cord of SOD1G93A mice (Giribaldi et al., 2013). To assess
whether dampening mGluR1 expression, leading also to reduction of
the expression of mGluR5, could modify this abnormal effect, we per-
formed experiments comparing the release of [3H]D-Asp induced by the
mGluR1/5 agonist 3,5-DHPG in WT, SOD1G93A, SOD1G93AGrm1crv4/+and
Grm1crv4/+ mice. Fig. 8 shows that [3H]D-Asp release evoked by
0.3 μM 3,5-DHPG was increased in SOD1G93A with respect to WT mice.
Of note, the 3,5-DHPG-evoked release was reduced to control levels in
SOD1G93AGrm1crv4/+ mice. No differences were observed in comparing
WT, SOD1G93AGrm1crv4/+ and Grm1crv4/+mice. Also the 30 μM 3,5-
DHPG-evoked release of [3H]D-Asp was increased in SOD1G93A mice. [3H]
D-Asp release was even signiﬁcantly lower in SOD1G93AGrm1crv4/+and
Grm1crv4/+ mice when compared to WT mice. Thus, halving the dosage
of mGluR1 inSODG93A background normalizes the excessive Group I
mGluR-induced [3H]D-Asp release.
Discussion
Glu-mediated excitotoxicity is one of themajor determinants of ALS.
In a previous work we have demonstrated that abnormal release of
excitatory amino acid neurotransmitters occurs at the spinal cord level
in the SOD1G93A mouse model of human ALS (Giribaldi et al., 2013;
Fig. 7. Electron microscopy analysis of mitochondria in spinal cord fromWT, SOD1G93A, SOD1G93AGrm1crv4/+and Grm1crv4/+mice. Ultrathin sections (60 nm) from lumbar (L4/L5) spinal
cord were stained with uranyl acetate and Sato's lead and examined by EM coupled to a high-resolution CCD camera. Normal and swollen/vacuolated mitochondria were quantiﬁed in
perikarya, dendrites,myelinated axons and axon terminals inmotoneurons. Representative photomicrographs (A; scale bar: 1 μm)and quantitative analysis (B) are reported. Black arrows
indicate normal (N) and swollen (S) or vacuolated (V)mitochondria. Data are expressed as number/μmof normal and swollen/vacuolatedmitochondria and aremeans ± SEM of 40mi-
croscopic ﬁelds, at least, from 3 mice per group, corresponding to a total area of about 800 μm2. Normal mitochondria were dramatically reduced and swollen/vacuolated mitochondria
increased in SOD1G93Amice. In SOD1G93AGrm1crv4/+, normalmitochondria were signiﬁcantly augmented in perikarya, dendrites and axon terminals and swollen/vacuolatedmitochondria
were signiﬁcantly reduced in perikarya and dendrites. *p b 0.05, **p b 0.01, ***p b 0.001 vs.WT; #p b 0.05, ##p b 0.01, ###p b 0.001 vs. SOD1G93A (one-wayANOVAand Bartlett's post-hoc
tests).
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ies, it emerged that mGluR1 and mGluR5 could play a role in the pro-
cess. Indeed, exposure to the mGluR1/5 agonist 3,5-DHPG at
concentrations N0.3 μM stimulated Glu release in the lumbar spinal
cord of both control and SOD1G93A mice. At variance, concentrations of
3,5-DHPG ≤0.3 μM increased Glu release in SOD1G93A mice only. The
use of selective antagonists and of confocal and electron microscopy
experiments indicated the involvement of presynaptically located
mGluR1 and mGluR5, mGluR5 being preferentially involved in thehigh potency effects of 3,5-DHPG (Giribaldi et al., 2013). Therefore, acti-
vation of mGluR1 and mGluR5 produces abnormal glutamate release in
SOD1G93Amice, suggesting that these receptors are implicated in ALS. In
order to support this hypothesis, we studied here the impact of mGluR1
in the progress of experimental ALS by down-regulating mGluR1 ex-
pression in the SOD1G93A genetic background. The results obtained indi-
cate that reducing mGluR1 ameliorates the course of the disease,
attaining a signiﬁcant increase of life span as well as a delay in the dis-
ease onset and progression and ameliorates a number of histological
Fig. 8. Glutamate release evoked by 3,5-DHPG in spinal cord from WT, SOD1G93A,
SOD1G93AGrm1crv4/+ and Grm1crv4/+ mice. Spinal cord synaptosomes were labeled with
[3H]D-Asp and exposed in superfusion to 0.3 and 30 μMof 3,5-DHPG. Superfusion samples
were counted for radioactivity. Results are expressed as per cent increase of basal release.
The abnormal 3,5-DHPG-evoked [3H]D-Asp release detected in SOD1G93A mice was
abolished in SOD1G93AGrm1crv4/+ mice. Data are means ± SEM of 8–10 independent ex-
periments (8–10 mice per group) run in triplicate.*p b 0.05 vs. WT; #p b 0.05,
##p b 0.001 vs. SOD1G93A (one-way ANOVA and Bonferroni post-hoc tests).
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mice.
Noteworthy, halvingmGluR1 expression also leads to a reduction of
mGluR5 in SOD1G93AGrm1crv4/+mouse spinal cord. On this basis, it could
be hypothesized that the presence of the genetic cerv4mutation in the
SOD1G93A background can reduce mGluR5 expression by an unknown
homeostatic mechanism, possibly linked to themolecular and function-
al interplay existing between the two Group I mGlu receptors (Fazio
et al., 2008; Rossi et al., 2012). Of note, also Grm1crv4/+ mice show
lower levels of mGluR5 compared to WT mice. Whichever the reason,
the lower levels of mGluR5 found in SOD1G93AGrm1crv4/+ mice suggest
that both Group I mGluR subtypes play a role in the functional and bio-
chemical changes observed. Further studies are in progress to clarify the
effects of mGluR5 dampening in the SOD1G93A mouse model of ALS.
A typical hallmark of ALS end stage is the massive loss of spinal cord
MNs. We showed here that halving mGluR1 in the SOD1G93A back-
ground signiﬁcantly increases the number of MNs still present in the
ventral horns of the affected lumbar spinal cord. This preservation
may be at the basis of the amelioration and, possibly, of the delayed
onset of symptoms above reported. Further studies aimed atmonitoring
the loss of MNs in SOD1G93AGrm1crv4/+ respect to SOD1G93Amice during
disease progression would help to strengthen this correlation.
MN damage in ALS is a non-cell autonomous event and this occur-
rence adds complexity to ALS etiology. Although neuron-restrictedmu-
tated SOD1 expression is sufﬁcient to cause MN death, mutated SOD1
expression in surrounding astrocytes and microglia inﬂuences the pro-
gression rate of neurodegeneration (Ilieva et al., 2009; Li et al., 2011). In
this scenario, astrocytes promise to play a pivotal role by affecting dis-
ease progression (Wang et al., 2011b; Yamanaka et al., 2008) and MN
vulnerability to excitotoxicity (Van Damme et al., 2007). Moreover, re-
duction (Boillée et al., 2006a) or ablation (Beers et al., 2006) of mutated
SOD1 expression in microglia produce beneﬁcial effects on disease du-
ration and extend survival in SOD1G93A mice. We observed a reduction
of astrogliosis and microgliosis in SOD1G93AGrm1crv4/+ mice, assessed
by monitoring GFAP and IBA-1 expression. Due to the close
relationship between neuronal and glial cells in ALS, these results, ob-
tained by directly and indirectly decreasing mGluR1 and mGluR5expression, support the concept that the two receptors play important
roles in ALS and that this effect is not mediated exclusively by neuron.
There is evidence supporting the hypothesis that oxidative stress
plays a role in MN death occurring in ALS (Lin and Beal, 2006;
Robberecht, 2000). It is known that MTs and CAT are neuroprotec-
tive through their intracellular role as radical and toxic metabolite
scavengers and many studies indicate that their expression/activity is
altered in ALS (Babu et al., 2008; Gong and Elliott, 2000; Nikolić-Kokić
et al., 2006; Ono et al., 2006). We found here that changes in MT and
CAT mRNA expression, found in SOD1G93A mice, are restored in
SOD1G93AGrm1crv4/+ mice. Interestingly, we have previously shown
that administration of mesenchymal stem cells to SOD1G93A mice im-
proved survival probability, slowed down disease progression and nor-
malized the MT up-regulation (Uccelli et al., 2012), suggesting a
relationship between MT mRNA expression and disease progression in
SOD1G93A mice. Thus, both mGluR1 down regulation and mesenchymal
stem cell administration, that prolong survival and ameliorate disease
hallmarks, pursue normalization of oxidative stress markers, thus sug-
gesting that this mechanismmay represent a common route for disease
rescue.
Mitochondrial damage, in the form of swollen/vacuolated organ-
elles, is one feature of ongoing MN degeneration in ALS (Boillée et al.,
2006a; Cozzolino and Carrì, 2012). Expression of mutant SOD1 genes
is strongly associatedwithmitochondrial damage in both presymptom-
atic and symptomatic stages of SOD1 mouse models of the human pa-
thology (Boillée et al., 2006a; Jaarsma et al., 2000, 2001). The present
study conﬁrms mitochondrial abnormalities in SOD1G93A mice and,
most interestingly, shows that double mutant SOD1G93AGrm1crv4/
+mice display lower levels of damaged mitochondria and higher levels
of normal mitochondria compared to SOD1G93A mice. A very recent
study awaiting conﬁrmation surprisingly proposes that disease progres-
sion is not directly linked to mitochondrial damage and MN death in
mutated SOD1 models (Parone et al., 2013). Even so, we believe that
our ﬁndings allow us to suggest that the higher number of normalmito-
chondriamay contribute, at least in part, to the slowdown ofMNdegen-
eration and possibly to the clinical amelioration in SOD1G93AGrm1crv4/
+mice.
GLT1 is reduced in ALS and this reduction has been presumed as a
major cause of excessive glutamate and excitotoxicity (Rothstein,
1995; Trotti et al., 2001). Accordingly, increase of GLT1 synthesis has
been proposed as a useful therapeutic approach (Ganel et al., 2006;
Rothstein et al., 2005), although recent human studies weakened this
hypothesis (Cudkowicz et al., 2013). Our data shows that the decreasing
mGluR1 andmGluR5 expression does notmodify the amount of GLT1 in
the spinal cord of SOD1G93AGrm1crv4/+ mice, thus suggesting that the
mechanisms leading to amelioration of disease progression in our
model are independent of the GLT1 function and are able to prevail
over the possible detrimental effects of the recorded GLT1 reduction.
The core hypothesis that originated the present work is that Glu-
driven excitotoxicity is sustained by abnormal mGluR1- and mGluR5-
induced Glu release. We have previously observed that 3,5-DHPG
induced abnormal Glu release from SOD1G93A mouse spinal cord
synaptosomes (Giribaldi et al., 2013). In order to verify whether this
abnormal releasemay be causally linked to the pathology,we examined
the 3,5-DHPG-induced Glu release in SOD1G93AGrm1crv4/+ mice. Note-
worthy, we found that mGluR1 reduction abolished the excessive re-
lease of Glu measured in SOD1G93A mice. Actually, Glu release, induced
by 30 μM 3,5-DHPG in SOD1G93AGrm1crv4/+ and Grm1crv4/+mice, was
even signiﬁcantly lower than inWTmice. We have shown that both re-
ceptors can sustain the excessive Glu release but the recruitment of
mGluR5 appears to be higher when lowering the agonist concentration;
the opposite is true for mGluR1. It is conceivable that genetic ablation of
mGluR1 produces the release-reducing effects more efﬁciently when
these receptors play a pivotal role, i.e. at high 3,5-DHPG concentrations.
The reduction of release observed also in Grm1crv4/+ mice, using 30 μM
3,5-DHPG, supports this hypothesis. Taken together, these results
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ease progression and suggest that the release of Glu plays a role in
excitotoxicity in ALS. Clearly, Glu release is not the only cause of the pa-
thology, since abolishing excessive release does not prevent the appear-
ance of symptoms and death. On the other hand, abnormal release is not
the only cause of excessive Glu: inhibition of astrocytic Glu uptake rep-
resents another important mechanism (Rothstein et al., 1995). These
results are also in line with the notion that ALS is likely a multifactorial
disease. Further studies at more precocious stages of the disease might
be useful to elucidate this issue.
On the depicted ground, pharmacological treatments aimed to coun-
teract the activity of Group I mGluRs might be beneﬁcial in ALS. It has
been shown that chronic treatment with the prototypic mGluR5 antag-
onist MPEP attenuates cell death, delays the onset of motor symptoms,
and prolongs survival in SOD1G93A mutant mice, although only to some
extent (Rossi et al., 2008). While effective mGluR1 antagonists are only
pre-clinically available at present, new, selective andpotentmGluR5 an-
tagonists are now under clinical trials. One of these, fenobam, was test-
ed in humans for its anxiolytic and analgesic activity and in fragile X
syndrome (Berry-Kravis et al., 2009; Porter et al., 2005) and exhibited
a good therapeutic proﬁle without signiﬁcant adverse effects. Another
compound, AFQ056,was clinically tested for Parkinson disease dyskine-
sia and fragile X syndrome (Berg et al., 2011; Levenga et al., 2011), again
showing an attractive safety proﬁle. Once tested in vivo in the ALS ani-
mal models these drugs may be directly translated to the clinic.
Conclusions
The present genetically-based evidence emphasizes the crucial role
played by both mGluR1 and mGluR5 in determining ALS symptoms, at
least in the SOD1G93A mouse model. In fact, halving mGluR1 expression
in SOD1/G93A background led to a decrease also of mGluR5. Interest-
ingly, the reduced level of Group ImGluRs determined increased surviv-
al, amelioration of disease symptoms, MN protection from death, and
improved biochemical and histological readout of disease in SOD1G93A
mice. These ﬁndings allow us to propose the excessive activity of
these receptors as a novel mechanism contributing to the disease, thus
providing the basis for novel pharmacological approaches to ALS by
using drugs that selectively block Group I mGluRs.
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